It doesn’t matter who is President. The old economy is gone...
The truth is, if you’re working for a company right now your income is getting lower every year—even as we speak, and it’s not going to stop.
Since 1993, income for people ages 18-35 has gone from $36,000 to $33,000. That may seem like a small amount, but it’s not.
It's the first time ever that income has gone down over such a long period (more than a year).
Counting on college to help you get a good job, a good promotion, a retirement plan, stability, security—that’s a thing of the past...
Sadly, we’re witnessing the slow death of the salaried employee, because everything that used to be safe is not.
In the meantime, debt is going through the roof. Student loan debt, housing debt, credit card debt...
What’s worse, asset values such as houses, education, and stocks are going up, up and up.
And as I said, incomes and job satisfaction are dropping off a cliff.
What does this have to do with biotech?
Biotech stocks surged on the news of Donald Trump’s victory over Hillary Clinton.
2015 was a disastrous year for biotech stocks. For most of the year the market struggled to find solid footing when it came to biotech stocks.
It actually boiled down to a tweet.
Hillary Clinton sent the industry into a tailspin when she tweeted that there was price gouging going on in the pharmaceutical market and promised to enact policies to prevent “profiteering” in the world of biotechs.
Today, a recent report by Medtech Solutions (formerly Millennium Research Group) determined that the biotech industry is set to explode.
And specifically, the stem cell therapy market as a whole is set for blast off.
According to Medtech, the stem cell market is growing at a rapid pace despite its current state of infancy.
While there are currently only two on the market, by 2017, almost 90 different products are expected to become available.
Stem cells have the potential to cure diseases that are currently incurable and can provide lasting treatments for many chronic disorders—from heart disease and blindness, to severe burns and diabetes-related complications.
Public acceptance, regulatory approval, and the success of clinical trials will determine how the rest of the U.S. market for stem cell therapies will develop.
What’s indisputable is there is vast market potential in this use of stem cell technology.
In fact, I recommended Verastem, Inc. NASDAQ: VSTM) on November 1st, a best performer in the development of drugs targeting cancer stem cells, amongst all NYSE and NASDAQ listed stocks in the healthcare sector.
Another stem cell therapy stock to watch is StemCells Inc. (NASDAQ: STEM) up 47% in August after announcing it would merge with Microbot Medical Ltd., with plans to develop robotics-based medical devices.
I’ve had Fate Therapeutics Inc. (NASDAQ: FATE) on watch since January this year at $2.63 and in February when it dropped to $2.22, they develop programmed cellular immunotherapies for cancer and immune disorders. It was recently up 20% in the day to $3.18 after announcing a private financing.
Other Micro-cap biotech companies that I would consider as flavors of the day at the moment include:
MannKind Corporation (NASDAQ: MNKD) +33%
EnteroMedics Inc. (NASDAQ: ETRM) + 31%
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) +26%
Galectin Therapeutics Inc. (NASDAQ: GALT) +23%
Osiris Therapeutics, Inc. (NASDAQ: OSIR) +23%
Immune Design Corp (NASDAQ: IMDZ) +61%
Trevena Inc. (NASDAQ: TRVN) +22%
With more market clarity, it’s a safe bet that we will be finding even more low-priced quality biotech stocks.